AroCell became this week a member of SwedenBIO, an industry organization for Swedish Life Science companies. The purpose of the membership is to take part in the broad life science development in Sweden and to participate in SwedenBIOs networks and network meetings.
AroCell develops a biomarker test that can support the treatment, prognosis, and follow-up of cancer patients. SwedenBIO has a large network that includes everything from researchers, life science companies, financiers and various service companies working together for a competitive life science industry in Sweden. It contributes to an innovative environment for the entire life science industry, and AroCell is now a part of it.
"We are pleased to be part of the SwedenBIOs network and promote the Swedish Life Science growth. It is important for us to operate both nationally and internationally and to establish strong relationships with both oncology and other healthcare companies, "says Michael Brobjer, CEO of AroCell.
For more information:
Michael Brobjer, CEO
Telephone: +46(0)18 50 30 20
E-mail: michael.brobjer@arocell.com
This information was submitted for publication through the agency of Michael Brobjer, January 25, 2019 at 15:30 hours.
About AroCell
AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210™ ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90.
For more information; www.arocell.com
Attachment
